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Background and objective: Our aim was to study the regulatory role of serotonin [(5-
hydroxytryptamine (5-HT)] on two key nodes in the cognitive control networks – the anterior
cingulate cortex (ACC) and the dorsolateral prefrontal cortex (DLPFC).We hypothesized that
increasing the levels of 5-HT would preferentially modulate the activity in ACC during cog-
nitive control during interference by negative affects compared to cognitive control during
interference by a superimposed cognitive task.
Methods: We performed a functional magnetic resonance imaging investigation on 11
healthy individuals, comparing the effects of the selective 5-HT reuptake inhibitor esci-
talopram on brain oxygenation level dependent signals in the ACC and the DLPFC using
affective and cognitive counting Stroop paradigms (aStroop and cStroop).
Results: Escitalopram significantly decreased the activity in rostral ACC during aStroop
compared to cStroop (p<0.05). In the absence of escitalopram, both aStroop and cStroop
significantly activated ACC and DLPFC (Z ≥2.3, p<0.05).
Conclusion:We conclude that escitalopram in a region and task specific manner modified
the cognitive control networks and preferentially decreased activity induced by affective
interference in the ACC.
Keywords: cognitive control, 5-hydroxytryptamine, serotonin uptake inhibitors, magnetic resonance imaging,
prefrontal cortex
INTRODUCTION
The cognitive control of behavior refers to a set of executive func-
tions that enables a person to maintain goal directed activity in
a changing environment by using continuously updated problem
solving (1, 2). Impaired cognitive control of behavior is character-
istic of a number of psychiatric disorders, such as depression (3)
and schizophrenia (4).
Variations of the Stroop task have been extensively used to
investigate cognitive control in humans (5, 6). The Stroop task
requires that a person can maintain focused attention and is capa-
ble of continuous problem solving in the presence of conflicting
or distracting stimuli. The counting Stroop task (cStroop) is a
version of the task that was created for use in brain scanning
experiments (7). In the cStroop, a person reports the number of
words presented on a screen. The words represent a numeral and
the conflict depends on whether the number of words reflects the
numeral content. The cStroop was also further developed into a
version with distracting affective stimuli – the affective counting
Stroop task (aStroop) (8).
Using the Stroop tasks, two brain areas in particular have been
identified as mediators of cognitive control: the anterior cingu-
late cortex (ACC) and the dorsolateral prefrontal cortex (DLPFC)
(9). The ACC appears to be involved in detecting errors in form
of interfering stimuli (10, 11) while the DLPFC appears to be
involved in resolving cognitive conflicts through the use of focused
attention and problem solving (12).
The neural activity during Stroop tasks in these two regions are
found to be deranged in a number of psychiatric disease states. In a
study on unipolar depression, both ACC and DLPFC were hyper-
active during a version of cStroop compared to healthy controls
(13). Healthy controls compared to patients with euthymic bipolar
disorder exhibited relatively increased activation in middle frontal
gyrus (14). Schizophrenia subjects showed significantly increased
pattern of activation in the ACC (15). In obsessive compulsive dis-
order, the ACC showed weaker activation during a version of the
cStroop, compared with healthy controls (16).
Several lines of research suggest that serotonin (5-
hydroxytryptamine, 5-HT) is involved in the regulation of
cognition in the prefrontal cortex (17). Research conducted in
non-human primates and rodents suggests that 5-HT in the pre-
frontal cortex plays a modulatory role in spatial working memory
(18). Also, it is critical for cognitive flexibility; when depleted it
results in perseverative behaviors (19, 20). In addition, 5-HT is rel-
evant for behavioral inhibition since elevated or reduced prefrontal
5-HT level is followed by deficits in impulse control (21, 22). 5-HT
is proposed to be linked especially to those aspects of impulsivity
that involves emotionally salient rewards or feedback (23).
Recent studies suggest 5-HT is one of the central neurochemi-
cal regulators of the cognitive control network (24, 25). Both key
nodes in this network – the ACC and the DLPFC – are inner-
vated by ascending raphe nuclei 5-HT projections; the ACC more
densely so than the DLPFC (26). Decreasing the availability of
www.frontiersin.org February 2014 | Volume 5 | Article 21 | 1
Rahm et al. Escitalopram effects on Stroop tasks
5-HT, using low tryptophan diets, increased the neural activity
both in the ACC and DLPFC during the cStroop as measured by
the blood oxygen level dependant (BOLD) response (27). Also,
decreased availability of 5-HT increased the impact of affective
distracting stimuli during aStroop as measured by increased reac-
tion times (28). However, the corresponding brain imaging data
for aStroop did not show any significant effects in terms of BOLD
response in the ACC or DLPFC. Conversely, a 2-week administra-
tion of a selective 5-HT reuptake inhibitor agent (SSRI), increasing
the availability of 5-HT, decreased the neural activity in the ACC
during cStroop in a cohort of depressed patients (29).
The antidepressant effects of SSRI usually take 2 or 3 weeks
of continuous treatment to become evident (30). However there
is evidence of positive treatment effects on mood regulation the
first 5 days (31). In fact, two studies have documented the effects
on emotional and cognitive functioning after a single-dose of SSRI
(32, 33). Healthy volunteers became more sensitive to fearful faces,
while the opposite effect was noted among the depressed subjects.
Against this background, we suggested a correlation between the
level of 5-HT availability and the neural activity in the key nodes
of the cognitive control network during Stroop tasks, especially for
aStroop in the ACC. We hypothesized that increasing the availabil-
ity of 5-HT with an acute dose of SSRI reduces affective activation
in the cognitive control circuit.
We set up an experiment in which we used functional magnetic
resonance in conjunction with escitalopram, a highly selective
SSRI that unlike other SSRI agents has affinity only for the 5-HT
transporter (34), to study the acute effects on neural activity in
ACC and DLPFC among healthy controls during their perfor-
mance of the cStroop and aStroop tasks and analyzed the data
using both a cluster corrected whole brain analysis and a voxel
corrected region of interest (ROI) analysis.
MATERIALS AND METHODS
PARTICIPANTS
This case–control study was initially a pilot study where 11 healthy
subjects (eight males, three females; mean age: 34.9 years, SD:
7.8 years) were recruited by local advertisement. All participants
were investigated with the Edinburgh Handedness Inventory and
were right handed. We used questionnaires (the Structured Clin-
ical Interview for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition – SCID-1, and the Alcohol and Drug Use
Disorders Identification Tests respectively – AUDIT and DUDIT)
and a structured clinical interview to rule out any history of neuro-
logic or psychiatric illness, including substance abuse. The ethics
committee of the Karolinska Institutet approved the study and
the participants signed informed consent after the procedures had
been fully explained.
EXPERIMENTAL DESIGN
Off camera, prior to the start of the experiment, the subjects were
instructed how to perform the Stroop tasks and completed a com-
puterized, 1-min training version. Each subject was then scanned
on two occasions the same day, each session included both aStroop
and cStroop tasks. The second scanning session was performed
4 h after ingestion of a tablet of 10 mg of escitalopram, corre-
sponding to the expected maximum of plasma concentration of
escitalopram. The subjects were blinded to the content of the tablet
and were informed that it could be either a psychoactive drug or
placebo.
The Stroop tasks were programed in E-Prime v 1.0 (Psychology
Software Tools, 2002). A mixed block design was used. Every block
consisted of a series of 10 words written in white letters against a
black background. The words were presented one at a time with an
interval of 1.5 s. Each word was shown in one to four copies. The
subjects were instructed to consecutively report by button-press
the number of copies. See Figure 1.
The cStroop (7) and aStroop (8) were programed in E-Prime v
1.0 (Psychology Software Tools, Sharpsburg, PA, USA) in a mixed
block design consisting of 10 trials of 10 categorized interference
words and 10 neutral words. This was repeated four times in which
aStroop and cStroop blocks randomly alternated twice. Each trial
began and ended with a 30-s period with a fixation spot. The
words were presented in white letters every 1.5 s against a black
background and stayed on the screen for 1.0 s. A black screen
was shown between the two stimuli. During both aStroop and
cStroop, subjects reported by button-press the number of words
(one to four) appearing on the screen, regardless of word mean-
ing. Neutral word-control trials (e.g., “table” written three times)
appeared intertwined with interference trials containing number
words that are incongruent with the correct response (e.g., “two”
written four times). aStroop contained the same kind of neutral
word-control trials, while interference trials contained emotional
words (e.g., “death” written three times; Figure 1). The inter-
ference words were emotionally charged words (in the aStroop
task) or numerals (in the cStroop task). The neutral and affec-
tive words were chosen from the word database affective norms
FIGURE 1 | Study design. We used a combined Stroop paradigm: affective
counting Stroop (aStroop), and cognitive counting Stroop (cStroop)
intertwined. The test subjects were examined in two scanning sessions,
the second one 4 h after intake of escitalopram (corresponding to C-max).
The subjects were blinded to the tablet, and they were instructed that they
were to see sets of one to four identical words appearing on the screen and
that they should report, via button-press, the number of words in each set,
regardless of what the words are.
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for English words (ANEW) (35), which is a compilation of words
characterized on the affective dimensions of valence, arousal and
dominance, and on the discrete emotional categories of happiness,
sadness, fear, disgust, and anger. The neutral words denoted house-
hold articles. As affective words we chose those with the highest
emotional valence and arousal in the categories of sadness and fear.
The words were translated into Swedish, taking into account the
number of syllables and the length of the words. The same neu-
tral and affective words never appeared twice in the same session
and the presentation order was randomized. The numerals (“one,”
“two,” “three,” or “four”) were chosen randomly (with help from
www.random.org), but congruent combinations of numerals and
number of copies were excluded. No feedback of the responses
accuracy or reaction time was given to the participants.
We decided not to have a placebo arm since we assumed that
the placebo effect would be similar in both aStroop and cStroop
and therefore could be ruled out when comparing the two.
DATA ACQUISITION
Participants were scanned at the Karolinska University Hospital
Huddinge, in a 3-T Siemens TrioTim, with a quadrature head
coil. They were instructed to avoid psychoactive substances the
same morning as the day of scanning and the night before. A
T1-weighted anatomical scan (MP-RAGE, 128 slices, repetition
time (TR) 2400 ms, echo time (TE) 3.44 ms, with a voxel size of
1.3 mm× 1.3 mm× 1.3 mm) was obtained for each subject, which
took about 6 min. We then did functional scanning while subjects
performed the experimental tasks, and this took about 12 min.
BOLD sensitive T2*-weighted echo planar images were acquired
comprising 28 slices covering the whole brain. The voxel resolu-
tion was 1.96 mm× 1.96 mm× 4.80 mm. The TR was 1.5 s. The
TE was 30 ms, and the flip angle was set to 90°. We chose to divide
the total experimental session into four separate 3-min-runs (one
Stroop task in each) in order to minimize habituation, and to
achieve two pairs of runs for investigations of the intrasubject
variability. Each run consisted of a total of 120 volumes. The first
six (dummy) volumes of each run were discarded to allow for
T1 equilibration effects. In total, the subjects were in the magnetic
resonance imaging (MRI) scanner for 25–30 min. To rule out radi-
ological signs of pathology, a senior consultant in neuroradiology
(Maria Kristoffersen-Wiberg) evaluated the anatomical scans of
each subject.
IMAGE ANALYSIS
All statistical analyses were done in the FSL suite. Statistical para-
metric mapping was performed using the FSL 4.1.5 software
(FMRIB, Oxford University, UK) and data processing was carried
out using FMRI expert analysis tool (FEAT) Version 5.98. Each
subjects run was corrected for head motion using MCFLIRT (36).
Sharp spikes of motion were removed using fsl_motion_outliers
and non-brain tissue was cleaned using BET (37). To account
for time difference in slice acquisition, we performed slice-timing
correction using Fourier-space time-series phase shifting. To com-
pensate for anatomical variability after registration and to permit
application of Gaussian random field theory for the corrected sta-
tistical reference, the functional data was smoothed using a Gauss-
ian kernel that was set to full-width half-maximum (FWHM)
FIGURE 2 | fMRI results. (A,B) Brain activation during affective counting
Stroop (aStroop) and cognitive counting Stroop (cStroop), before (controls)
and after intake of escitalopram (cluster forming threshold Z ≥2.3,
corrected p=0.05, MNI z =29). In both Stroop conditions, there are
significant activations in anterior cingulate cortex (ACC) and dorsolateral
prefrontal cortex, key nodes in the neural cognitive control networks.
(C) A region of interest analysis of the ACC, where aStroop activates more
than cStroop before compared to after drug intake. For display purposes the
cluster shown in the image has an uncorrected threshold of 0.005, but the
peak voxel (x, y, z : 6, 44, 12) survived a corrected threshold of p=0.05 (at
the voxel level, using Gaussian random field theory).
8 mm. The grand-mean intensity of the entire four dimensional
dataset was normalized by a single multiplicative factor, and phys-
iological noise was filtered using a high-pass temporal filter set at
100 s. The parameter estimates (PE) were calculated for all brain
voxels using the general linear model and the contrast images
(COPE) were calculated by comparing the interference condition
with the neutral condition. The time-series statistical analysis was
carried out using FMRIBs improved linear model (FILM) with
local autocorrelation correction (38). Registration to high resolu-
tion structural and MNI152 (2 mm) standard space images was
carried out using FLIRT (39, 40).
We compared each subject’s activation before and after medica-
tion using a pairedT -test. We compared both types of Stroop tasks
in a paired T -test. We used a mixed effect analysis (FLAME 1 and
2) (41, 42). The Z statistical map was thresholded using a cluster
based method for multiple comparisons correction. Cluster form-
ing threshold was predetermined at Z ≥ 2.3 and each cluster was
tested for a significance at p= 0.05 (corrected, using a Gaussian
random field theory).
Post hoc, we also did a hypothesis driven ROI investigation in
restricted sets of voxels; these voxels corresponded to the ACC and
the middle frontal gyrus, which was used as a proxy for DLPFC.
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The ROI masks were derived from the probabilistic Harvard-
Oxford Cortical Atlas. Masks were unthresholded. The Z statis-
tical map was thresholded at the voxel level with the significance
threshold set to p= 0.05 (corrected, using Gaussian random field
theory).
RESULTS
WHOLE BRAIN ANALYSES
In the absence of escitalopram, aStroop significantly activated
two large clusters of voxels, including local maxima in left
occipital cortex (x, y, z : −56, −70, 22), left middle tempo-
ral gyrus (−62, −54, −2), left frontal pole (−24, 54, 36), left
middle frontal gyrus (−44, 24, 40), left precuneus cortex (−2,
−60, 10), left cingulate cortex (−6, −50, 28), and left amyg-
dala (−20, −12, −16) during interference trials with negatively
charged emotional words compared to non-interference trials
(neutral words) (p< 0.05, Z ≥ 2.3, Figure 2A, left panel, and
Table 1A). Similarly, in the absence of drug ingestion, cStroop
significantly activated left middle frontal gyrus (36, 14, 38), right
paracingulate gyrus (4, 40, 36), right middle frontal gyrus (48,
20, 42), right frontal orbital cortex (36, 32, 2), left insular cor-
tex (−32, 18, −8), and left inferior frontal gyrus (−48, 14, 6)
during interference trials compared to non-interference trials
(p< 0.05, Z ≥ 2.3, Figure 2B, left panel, and Table 1A). We did
not find any significant effects of escitalopram in our whole brain
analyses.
REGION OF INTEREST ANALYSES
To compare the effects of escitalopram on aStroop and cStroop
in the key nodes of the cognitive control networks, a hypothesis
Table 1 | Cluster characteristics.
Cluster
no.
Z
max
X
(mm)
Y
(mm)
Z
(mm)
Harvard-Oxford Cortical Atlas Voxels
A.WHOLE BRAINANALYSES
aStroop ctrl 2 4.91 −56 −70 22 52% Lateral occipital cortex, superior division 15714
1 4.47 −2 −60 10 44% Precuneus cortex 4278
aStroop SSRI 4 4.38 −26 −72 −16 70% Occipital fusiform gyrus 5293
3 4.12 −54 −16 56 37% Postcentral gyrus 4387
2 4.3 −42 32 −2 23% Frontal orbital cortex 2667
1 4.28 0 6 46 32% Juxtapositional lobule cortex 1137
cStroop ctrl 3 4.45 36 14 38 36% Middle frontal gyrus 6140
2 4.4 −32 18 −2 31% Insular cortex 1973
1 4.24 42 −46 36 18% Angular gyrus 1943
cStroop SSRI 5 4.43 −54 16 28 42% Inferior frontal gyrus, pars opercularis 10330
4 4.43 62 −54 −4 79% Middle temporal gyrus, temporooccipital part 7950
3 4.47 44 20 −12 42% Frontal orbital cortex 6533
2 4.33 −58 −46 −8 43% Middle temporal gyrus, temporooccipital part 3781
1 3.99 −14 −74 −46 No label found! 1120
B. ROI – DLPFC
cStroop> aStroop ctrl 1 6.2 46 22 32 40% Middle frontal gyrus 944
cStroop> aStroop SSRI 4 4.67 44 14 20 20% Inferior frontal gyrus, pars opercularis 65
3 4.17 −40 34 20 29% Middle frontal gyrus 10
2 4.09 34 10 32 26% Middle frontal gyrus 4
1 3.94 38 20 26 27% Middle frontal gyrus 2
C. ROI – ACC
cStroop> aStroop ctrl 1 5.01 8 30 38 61% Paracingulate gyrus 66
cStroop> aStroop SSRI 1 3.8 −6 14 46 57% Paracingulate gyrus 4
aStroop> cStroop ctrl 1 3.87 −6 52 2 75% Paracingulate gyrus 3
aStroop> cStroop SSRI – – – – – – –
(aStroop> cStroop
ctrl)> (aStroop> cStroop SSRI)
2 2.95 6 44 12 53% Cingulate gyrus, anterior division 1
1 2.92 8 44 8 53% Cingulate gyrus, anterior division 1
The table describes the localizations of the peak voxel in the clusters shown in Figure 2 and the region analyses of dorsolateral prefrontal cortex and anterior cingulate
cortex. Cluster forming threshold Z≥2.3, corrected p=0.05.The coordinates are in MNI standard. Since the Harvard-Oxford Cortical Atlas is a probabilistic atlas, the
anatomical localizations are reported in percentages.
aStroop, affective counting Stroop (incongruent>neutral words); cStroop, cognitive counting Stroop (incongruent>neutral words); ctrl, control situation; SSRI, after
intake of escitalopram; ROI, region of interest analysis; DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex.
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driven ROI analysis was performed post hoc in the ACC and
the DLPFC. In the absence of escitalopram, aStroop significantly
activated rostral ACC compared to cStroop (aStroop> cStroop,
corrected p< 0.05, Table 1C), while cStroop significantly activated
dorsal ACC and DLPFC compared to aStroop (cStroop> aStroop,
corrected p< 0.05, Tables 1B,C). Ten milligrams of escitalopram
decreased the BOLD signal in rostral ACC for the aStroop contrast
(aStroop> cStroop, corrected p< 0.05, Table 1B), and left intact
the BOLD signal in dorsal ACC and DLPFC for the cStroop con-
trast (cStroop> aStroop, corrected p< 0.05, Tables 1B,C). When
the effects of escitalopram were compared, the rostral ACC dur-
ing aStroop turned out to be significantly more activated before
compared to after drug intake (corrected p< 0.05, Figure 2C).
The peak voxel (x, y, z : 6, 44, 12) survived a corrected threshold of
p= 0.05 (at the voxel level, using Gaussian random field theory).
The difference was primarily driven by the aStroop after> before
escitalopram contrast (Figure 3). No other significant difference
was noted in the effects of escitalopram in medial or lateral PFC.
DISCUSSION
Escitalopram did not change the neural activations of aStroop and
cStroop studied separately. However, in support of our hypothe-
sis, an acute dose of SSRI significantly decreased the activation
in ACC during aStroop as compared to cStroop. Our finding is
consistent with earlier findings, in which increased availability of
5-HT has been shown to reduce the BOLD response in limbic and
paralimbic brain regions during exposition to negative emotional
stimuli (25).
The voxels that represented the largest difference are located in
the rostral part of the ACC. This is in agreement with earlier stud-
ies showing that the distribution of 5-HT transporters is denser in
the rostral ACC (43) compared to the dorsal ACC, as well as with
the putative functional division of the ACC, where rostral ACC is
more involved in emotional processing while the dorsal part of the
ACC has a more cognitive profile (44).
An interpretation that we favor is that escitalopram by reducing
the impact of negative emotions on brain activity made the bur-
den of the affective interference less intense. Our results suggest a
mechanism by which SSRI may resolve psychopathological states
such as depression or anxiety. Furthermore, our results indicate
that SSRI may have an effect already during the initial days of
treatment.
It cannot be ruled out that these effects of escitalopram on
prefrontal cortex are secondary to effects on other brain regions,
such as amygdala, a region in the temporal lobe that is heavily
innervated with serotonergic raphe nuclei neurons.
Our study has some limitations. First, the lack of placebo arm is
a weakness in our study. We assumed that the placebo effects would
be the same in both experimental conditions, aStroop and cStroop,
and that a placebo arm therefore would be redundant. However,
there may still be some placebo effects remaining such that affects
could be more sensitive to placebo effects than cognitive processes.
We used the same affective words in all three trials (the training
session and the two experimental sessions). To avoid sensitization
effects, we used a large number of words (80) and presented the
words in a randomized way. We also assumed that if there were any
training effects, they would appear during the first few minutes of
FIGURE 3 | Blood oxygen level dependant changes in the right ACC.
The BOLD percentage changes in the right rostral anterior cingulate cortex
for affective counting Stroop (aStroop) and cognitive counting Stroop
(cStroop) before and after intake of escitalopram. The differences were not
statistically significant. The mask was smoothed with a Gaussian kernel set
to 1.5 mm, surrounding the peak voxel shown in Figure 2A (x, y, z : 6,
44, 12).
exposition to the task, i.e., during the training session prior to the
experiment. However, it cannot be ruled out that training effects
may continue longer than that; our experimental design did not
allow us to control for that. Furthermore, we lack behavioral data,
due to technical problems with the handheld button box. However,
none of the subjects reported any problems in understanding or
performing the Stroop tasks, and under control conditions both
aStroop and cStroop activated the key nodes of the cognitive con-
trol network, the ACC and DLPFC, indicating that a true cognitive
control situation induced by the Stroop tasks really occurred. Fur-
thermore, when the first method (cluster corrected whole brain
analysis) did not show any significant differences after intake of
escitalopram, and we did not want to conveniently change the clus-
ter forming threshold, we chose post hoc to do a more anatomically
based voxel corrected ROI analysis. Finally, we identify the small
number of test persons (N = 11) as a limitation to our study.
In future studies, it would be interesting to include patients
with known cognitive control impairment and also to investigate
whether there are any differences between aStroop and cStroop
regarding the sensitivity to training effects and to placebo effects.
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